Shingrix for the prevention of shingles in at-risk adults aged 18 and over is accepted for review by China National Medical Products Administration – GSK
GSK plc announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted for review the regulatory application of Shingrix (Recombinant… read more.